Advances in Development of Thermostable mRNA-LNP Formulations

Time: 2:45 pm
day: Day One Track B PM


  • Showcasing development of the first mRNA vaccine developed by Abogen in China, but approved in Indonesia for emergency authorisation use
  • Sharing technical insights into Abogen’s mRNA COVID vaccine which can be stored at 2-8 degrees Celsius whilst similar vaccines from BioNTech-Pfizer and Moderna require much lower storage temperatures of -70 and -20 degrees Celsius
  • Highlighting Abogen’s recent progress in development of frozen and lyophilised mRNA-lipid nanoparticle formulations for conventional use